NCT06427694View on ClinicalTrials.gov

Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

February 11, 2030

Conditions
Acute Coronary Syndromes
Interventions
DRUG

Aldesleukin

IL2 antagonist

DRUG

Dextrose 5% in water

matched placebo to active

Trial Locations (1)

CB20QQ

RECRUITING

Addenbrooke's Hospital, Cambridge

All Listed Sponsors
lead

Cambridge University Hospitals NHS Foundation Trust

OTHER